Leerink Partnrs Forecasts Reduced Earnings for Penumbra

Penumbra, Inc. (NYSE:PEN - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2026 earnings per share estimates for Penumbra in a research report issued to clients and investors on Thursday, April 24th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn $5.53 per share for the year, down from their prior estimate of $5.54. The consensus estimate for Penumbra's current full-year earnings is $3.67 per share. Leerink Partnrs also issued estimates for Penumbra's FY2027 earnings at $7.09 EPS, FY2028 earnings at $8.26 EPS and FY2029 earnings at $9.34 EPS.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $324.14 million for the quarter, compared to the consensus estimate of $315.72 million. During the same period in the prior year, the business posted $0.41 earnings per share. The company's revenue for the quarter was up 16.3% on a year-over-year basis.

Several other research analysts also recently commented on PEN. BTIG Research restated a "buy" rating on shares of Penumbra in a report on Thursday, April 24th. Robert W. Baird increased their target price on Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. UBS Group reaffirmed a "buy" rating and set a $330.00 target price (up previously from $320.00) on shares of Penumbra in a research report on Thursday, April 24th. Canaccord Genuity Group increased their target price on Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Finally, Wells Fargo & Company increased their target price on Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Penumbra currently has an average rating of "Moderate Buy" and a consensus target price of $302.40.

Penumbra Trading Down 1.6 %

PEN traded down $4.65 during trading on Friday, hitting $292.26. 136,106 shares of the stock were exchanged, compared to its average volume of 424,567. The firm has a 50 day simple moving average of $276.75 and a 200 day simple moving average of $256.16. The firm has a market cap of $11.32 billion, a price-to-earnings ratio of 859.59, a P/E/G ratio of 2.83 and a beta of 0.56. Penumbra has a 1 year low of $148.00 and a 1 year high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01.

Insider Buying and Selling

In other Penumbra news, Director Thomas Wilder sold 360 shares of Penumbra stock in a transaction on Monday, March 31st. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80. Following the sale, the director now owns 4,533 shares of the company's stock, valued at $1,199,341.14. The trade was a 7.36 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Adam Elsesser sold 61,600 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the transaction, the chief executive officer now directly owns 16,376 shares in the company, valued at approximately $4,644,069.84. The trade was a 79.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 140,446 shares of company stock valued at $39,543,953. 5.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Quadrant Capital Group LLC boosted its position in shares of Penumbra by 6.6% during the 4th quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock valued at $150,000 after acquiring an additional 39 shares during the last quarter. Pallas Capital Advisors LLC boosted its stake in Penumbra by 3.8% during the fourth quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company's stock worth $263,000 after buying an additional 41 shares during the period. Baker Avenue Asset Management LP increased its position in shares of Penumbra by 1.6% during the fourth quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company's stock valued at $791,000 after acquiring an additional 53 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of Penumbra by 1.0% in the 4th quarter. Pacer Advisors Inc. now owns 5,721 shares of the company's stock valued at $1,359,000 after acquiring an additional 57 shares during the period. Finally, Fifth Third Bancorp lifted its holdings in shares of Penumbra by 16.4% in the 1st quarter. Fifth Third Bancorp now owns 404 shares of the company's stock worth $108,000 after acquiring an additional 57 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.